Previous 10 | Next 10 |
Amneal Pharmaceuticals (NYSE: AMRX ) Q3 results : More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ): Q3 Non-GAAP EPS of $0.04 misses by $0.09 ; GAAP EPS of -$2.03 misses by $2.10 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
‒ Q3 2019 Net Revenue of $378 million; GAAP Loss per share of ($2.03); Adjusted Diluted EPS (1) of $0.04 ‒ ‒ Positive Cash Flow from Operations of $140 million ‒ ‒ Executing on Near-Term Strategic Actions to Accelerate Business Performance ...
‒ Expands Amneal’s Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug ‒ Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into a licensing agreement with Kashiv BioSciences, LLC for the development and commer...
AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...
Trade uncertainty is likely to remain an issue until improving trade relations between China and the United States results in a signed agreement, creating market opportunities for investors. There's no telling what stocks will pop the most, but our most recent research suggests dividend-payi...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Invega ® (paliperidone) extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg. “We are pleased to have received approval on and launched a generic version of Invega, on...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time ...
After losing more than 77% of its total enterprise value in less than four years, Akorn, Inc. ( AKRX ) is a name to be followed carefully. The most significant risk is the company’s financial debt, which does not justify the current low valuation. Besides, Akorn recently announced tha...
- Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway - Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Amicar ® (am...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...